Event context and recent price moves

AdaptHealth (AHCO) has drawn attention after recent share price moves, with the stock last closing at US$11.20. Investors are weighing this level against the company’s fundamentals and recent total return profile.

The recent 7 day share price return of 13.0% and 30 day share price return of 20.0% have improved sentiment around AdaptHealth, although the 5 year total shareholder return of 69.8% remains weak, suggesting longer term momentum has faded.

If you are comparing AdaptHealth with other opportunities in healthcare, this is a good moment to broaden your search using our screener for 34 healthcare AI stocks.

So with AdaptHealth trading at US$11.20, an intrinsic value estimate suggesting a sizeable discount, and a mixed return record, should you view this as a potential entry point, or assume the market is already pricing in future growth?

Most Popular Narrative: 17.9% Overvalued

The most followed narrative puts AdaptHealth’s fair value at $9.50, below the last close of $11.20, and builds that view around how growth, margins, and contract economics evolve over time.

While AdaptHealth is well-positioned to benefit from the aging population and growing demand for home healthcare, thanks to its new large-scale, multi-year capitated contract that brings over $1 billion of locked-in revenue, the company faces significant near-term headwinds as the infrastructure investments needed to support this deal will sharply increase operating expenses and capital expenditures, which could suppress free cash flow and pressure net margins through 2026.

Want to see what turns that big contract and those margin pressures into a $9.50 fair value? The narrative leans heavily on long run earnings, revenue compounding, and a future earnings multiple that sits below broad healthcare levels, all stitched together with one required return hurdle that does a lot of work in the model.

Result: Fair Value of $9.50 (OVERVALUED)

However, there is still a chance that better than expected execution on the large capitated contract, or more favorable CMS outcomes, could challenge this cautious view.

Another View: DCF Flips The Story

While the popular narrative sees AdaptHealth as 17.9% overvalued at a fair value of $9.50, our DCF model points in the opposite direction. On this view, the shares trade about 68% below an estimated future cash flow value of $35.40, raising a very different question about what risk the market is pricing in.

If you want to see how this cash flow based view is built line by line, and how sensitive it is to the inputs used, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AdaptHealth for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 61 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between caution and opportunity, this is a good moment to move quickly, review the data directly, and weigh the 2 key rewards

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals far better, so widen the lens and test a few focused ideas.

• Hunt for quality at a discount by scanning 61 high quality undervalued stocks that pair stronger fundamentals with appealing pricing.
• Strengthen your income potential by reviewing 12 dividend fortresses that offer higher yields with an emphasis on durability.
• Prioritise resilience by checking 67 resilient stocks with low risk scores that combine lower risk scores with steadier financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.